Significant interactions with new antiretrovirals and psychotropic drugs

Annals of Pharmacotherapy

Volumn 33, Issue 4, 1999, Pages 461-473

  Tseng, Alice Lin In ^a,b   Foisy, Michelle M ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE

Author keywords

Antiretrovirals; Human immunodeficiency virus; Psychotropics

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRAMMUNE;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; DRUG EFFECT; DRUG EFFICACY; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; NEPHROLITHIASIS; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ANTIPSYCHOTIC AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; RETROVIRIDAE INFECTIONS;

EID: 0032940948     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18240     Document Type: Review

References (83)

1. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA panel. JAMA 1998;280:78-86.
2. Checkley GE, Thompson SC, Crofts N, Mijch AM, Judd FK. HIV in the mentally ill. Aust N Z J Psychiatry 1996;30:184-94.
3. Gournay K, Sandford T, Hohnson S, Thornicroft G. Dual diagnosis of severe mental health problems and substance abuse/dependence: a major priority for mental health nursing. J Psychiatr Ment Health Nurs 1997;4 (2):89-95.
4. Lyketsos CG, Hutton H, Fishman M, Schwartz J, Treisman GJ. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996;10: 1033-9.
5. Van der Ryst E, Strydom W, Scott C, Boshoff W, Joubert G, Els C. A high rate of psychiatric comorbidity in South African HIV/AIDS patients (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
6. Rabkin JG, Ferrando S. A "second life" agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency syndrome or the acquired immunodeficiency syndrome. Arch Gen Psychiatry 1997;54:1049-53.
7. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997;31:1040-58.
8. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with HIV. Clin Infect Dis 1996;23:685-93.
9. Sahai J. Risks and synergies from drug interactions. AIDS 1996;10(suppl 1):S21-5.
10. Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy (letter). AIDS 1998;12:228-30.
11. Acosta EP, Henry K, Weller D, Page LM, Bacon L, Rhame F, et al. Indinavir pharmacokinetics and relationships between exposure and antiviral effect (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
12. Harris M, Durakovic C, Rae S, Fransen S, Shillington A, Conway B, et al. Virologic response to indinavir/nevirapine/3TC correlates with indinavir trough concentrations (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
13. Patick AK, Mo H, Markowitz M, Appell K, Wu B, Musick L, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996;40:292-7.
14. Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, et al. Genotypic and phenotypic characterization of HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir. Antimicrob Agents Chemother 1998;42:2637-44.
15. Sampson MS, Barr MR, Torres RA, Hall G. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
16. Decks S, Grant R, Horton C, Simmonds N, Follansbee S, Eastman S. Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
17. Sampson M, Torres RA, Stein AJ, Cochrane JM, Taylor B, Mcintyre K, et al. Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
18. Hertogs K, Mellors JW, Schel P, Van Cauwenberghe A, Larder B, Kemp S, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
19. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
20. Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332-8.
21. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4.
22. Lee CA, Liang BH, Wu EY, Grettenberger HM, Sandoval TM, Zhang KE, et al. Prediction of nelfinavir mesylate (Viracept) clinical drug interactions based on in vitro human P450 metabolism studies (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
23. Product monograph. Rescriptor (delavirdine). Mississauga, ON: Pharmacia & Upjohn, 1998.
24. Product monograph. Viramune (nevirapine). Ridgefield, CT: Boehringer-Ingelheim Corp. USA, 1997.
25. Investigational drug brochure. Efavirenz (DMP-266). Wilmington, DE: The Dupont Merck Pharmaceutical Co., 1997.
26. Quellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6.
27. Ken B, Yuen G, Daniels R, Quart B, Anderson R. Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism (abstract). 4th National Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
28. Product monograph. Norvir (ritonavir). North Chicago: 1996.
29. Product monograph. Crixivan (indinavir). West Point, PA: Merck Frosst USA, 1997.
30. Fiske WD, Mayers D, Wagner K, Riddler S, Drusano G, Stein D, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals (abstract). 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
31. Fiske WD, Benedek IH, White SJ, Pepperess KA, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
32. Cox SR, Herman BD, Batts DH, Carel BJ, Carberry PA. Delavirdine and rifabutin: pharmacokinetic evaluation in HIV-1 patients with concentration-targeting of delavirdine (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
33. Panel of Clinical Practices for Treatment of HIV Infection DoHaHSD. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. December 1, 1998 Federal Register: 1997; www.hivatis.org.
34. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997;277:1962-9.
35. Workman C, Mussen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
36. Product monograph. Invirase (saquinavir). Mississauga, ON: Hoffmann-LaRoche Ltd., 1996.
37. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
38. Buss N. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions (abstract). 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998.
39. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-33.
40. Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, et al. Assessment of single-and multiple-dose interactions between ritonavir and saquinavir (abstract). XI International Conference on AIDS, Vancouver, BC, Canada, July 7-12, 1996.
41. Hsu A, Granneman GR, Japour A, Cao G, Locke C, Carothers L, et al. Evaluation of potential ritonavir and indinavir combination bid regimens (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
42. Hsu A, Granneman GR, Heath-Chiozzi M, Ashbrenner E, Manning L, Brooks R, et al. Indinavir can be taken with regular meals when administered with ritonavir (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
43. Mellors J, Japour AJ, Cameron DW, Farthing C, Cohen C, Markowitz M, et al. Ritonavir-saquinavir in protease inhibitor-naive patients after 72 weeks (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
44. Hsu A, Granneman GR, Molla A, Vasavanonda S, Japour A, Kempf D, et al. Ritonavir-containing dual protease inhibitor regimens may have synergistic antiviral effects in patients - based on in vitro model (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
45. Sadler BM, Eron J, Wakeford J, Pagano G, Rawls C, McCrea J, et al. Pharmacokinetics of 141W94 and indinavir after single-dose coadministration in HIV-positive volunteers (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
46. Sadler BM, Gillotin C, Chittick GE, Symonds WT. Pharmacokinetic drug interactions with amprenavir (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
47. Kerr B, Lee C, Yuen G, Anderson R, Daniels R, Grettenberger H, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor (abstract). 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
48. Squires K, Riddler S, Havlir D, Kerr B, Yeh K, Lewis R, et al. Co-administration of indinavir 1200 mg with nelfinavir 1250 mg in a twice-daily regimen: preliminary safety, pharmacokinetic activity (abstract). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
49. Manion D, Merrill DP, Hirsch MS. Combination drug regimens against multidrug resistant HIV-1 in vitro. 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
50. McCrea J, Buss N, Stone J, Carides A, Dru J, Stewart F, et al. Indinavir-saquinavir single dose pharmacokinetic study (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
51. Kravcik S, Sahai J, Kerr B, Anderson R, Buss N, Seguin I, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HTV+ patients (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
52. Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997;11:F117-20.
53. Merry C, Barry MG, Mulcahy FM, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV infected patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
54. Gallicano K, Sahai J, Kravcik S, Seguin I, Bristow N, Cameron DW. Nelfinavir increases plasma exposure of saquinavir in hard gel capsule in HIV+ patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
55. Zorrilla C, Clark R, Currier J, Squires K, Till M, Gersten M, et al. Women first: a study in HIV positive women of quadruple therapy: nelfinavir, saquinavir, stavudine (d4T) and lamivudine (3TC) (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
56. Burger DM, Hugen PWH, Prins JM, Van de Ende ME, Reiss P, Lange JMA. Pharmacokinetics of an indinavir/ritonavir 800/100 mg bid regimen (abstract). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
57. Flexner C, Hsu A, Kerr B, Wong C, Gallant J, Anderson R, et al. Steady-state pharmacokinetic interactions between ritonavir, nelfinavir, and the nelfinavir active metabolite M8 (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
58. Cox S, Sargent S, Para M, Freimuth W, Teugh C, Huang D, et al. Plasma viral load reduction in an open-label randomized study of Rescriptor in combination with zidovudine and two dose levels of indinavir compared to zidovudine, lamivudine, and indinavir in HIV-1 infected individuals (abstract). 7th Annual Canadian Conference on HIV/AIDS Research, Quebec City, PQ, Canada, April 30-May 3, 1998.
59. Ferry J, Herman B, Cox S, Carlson G, Carberry P. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic drug-drug interaction study in healthy adult volunteers (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
60. Freimuth W, Peaks S, Slater L, Cox S, Getchel L. An open-label randomized study of Rescriptor (delavirdine mesylate) plus nelfinavir, didanosine, and stavudine in quadruple treatment regimens in HIV-1 infected individuals (abstract). 7th Annual Canadian Conference on HIV/AIDS Research, Quebec City, PQ, Canada, April 30-May 3, 1998.
61. Cox S, Batts D, Stewart F, Buss N, Brown A, Chambers J, et al. Evaluation of the pharmacokinetic interaction between Saquinavir and delavirdine in healthy volunteers (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
62. Ferry J, Schneck D, Carlson G, Carberry P, Della-Coletta A, Gulotti B, et al. Evaluation of the pharmacokinetic interaction between ritonavir and delavirdine in healthy volunteers (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
63. Shelton MJ, Hewitt RG, Adams JM, Baldwin J, Della-Coletta A, Cox S, et al. Delavirdine mesylate pharmacokinetics during combination therapy with ritonavir (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997.
64. Gagnier P, Myers M, Lamson M, Greguski R, Love J, Chodakewitz J. Effect of nevirapine on pharmacokinetics of indinavir in HTV-1 patients (abstract). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
65. Skowron G, Leoung G, Kerr B, Dusek A, Anderson R, Beebe S, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998;12:1243-4.
66. Sahai J, Cameron W, Salgo M, Stewart F, Myers M, Lamson M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP). 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
67. Lamson M, Gagnier P, Greguski R, Myers M, Leonard J, Lauva I, et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of ritonavir (RTV) in HTV-1 patients. 4th National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
68. Piscitelli S, Vogel S, Sadler B, Fiske W, Metcalf J, Masur H, et al. Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HTV-infected patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
69. Data on file. Dupont Merck. Significant efavirenz-saquinavir interaction. 1998.
70. Fiske WD, Benedek IH, Joseph JL, Dennis S, O'Dea R, Hsu A, et al. Pharmacokinetics of efavirenz and ritonavir after multiple oral doses in healthy volunteers (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
71. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
72. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
73. Product monograph. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., 1997.
74. Polk HE, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, et al. Effects of ketoconazole and amprenavir (14 1W94) on P450 (CYP)3A4 activity measured by the erythromycin breath test (ERMBT) (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
75. Benedek IH, Joshi A, Fiske WD, White SJ, Jobes JL, Joseph JL, et al. Pharmacokinetic interaction studies in healthy volunteers with efavirenz and the macrolide antibiotics, azithromycin and clarithromycin (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
76. Joshi AS, Fiske WD, Benedek IH, White SJ, Joseph JL, Kornhauser DM. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
77. Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology 1998;135:22-6.
78. Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 1996;6:225-30.
79. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.
80. Product monograph. Nardil (phenelzine). Scarborough, ON, Canada: Parke-Davis, 1998.
81. Product monograph. Tryptan (L-tryptophan). Montreal, PQ, Canada: ICN Canada Ltd., 1997.
82. Product monograph. Loxapac (loxapine). St. Laurent, PQ, Canada: Wyeth-Ayerst Canada Inc., 1997.
83. Product monograph. Zyprexa (olanzapine). Scarborough, ON, Canada: Eli Lilly Canada Inc., 1997.